Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:11 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 5,052 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule 2 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

NCT07093008
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule, Placebo Tablet for Oral Suspension
Drug
Lead sponsor
AQILION AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 3, 2026, 2:11 AM EST
Completed Phase 3 Interventional Results available

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

NCT00808132
View directory record Official record
Conditions
Menopause, Osteoporosis
Interventions
bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg, conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
1,886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
143
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Nov 3, 2026, 2:11 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

NCT02063204
View directory record Official record
Conditions
Solid Tumours
Interventions
selumetinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Nov 3, 2026, 2:11 AM EST
Completed Phase 2 Interventional Results available

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

NCT05034952
View directory record Official record
Conditions
Acute Pain
Interventions
VX-548, HB/APAP, Placebo (matched to VX-548), Placebo (matched to HB/APAP)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
7
States / cities
Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Nov 3, 2026, 2:11 AM EST
Completed Phase 2 Interventional Results available

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

NCT00425555
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
Panobinostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Nov 3, 2026, 2:11 AM EST
Terminated Phase 2 Interventional Results available

LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma

NCT01820364
View directory record Official record
Conditions
Melanoma
Interventions
LGX818
Drug
Lead sponsor
Array BioPharma
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Nov 3, 2026, 2:11 AM EST
Not listed Phase 3 Interventional

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

NCT01050114
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A, Oxybutynin ER
Drug
Lead sponsor
Christopher Patrick Smith
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Nov 3, 2026, 2:11 AM EST
Recruiting Phase 2 Interventional

Confirmatory Clinical Study in Active Ulcerative Colitis

NCT07296315
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Low-dose MH002, High-dose MH002, Placebo
Drug
Lead sponsor
MRM Health NV
Industry
Eligibility
16 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Miami, Florida • Orlando, Florida • Palmetto Bay, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 3, 2026, 2:11 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

NCT00985933
View directory record Official record
Conditions
Healthy, Memory Impairment
Interventions
AZD8529, Placebo to match AZD8529
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Nov 3, 2026, 2:11 AM EST
Active, not recruiting Not applicable Interventional

Mindfulness And Placebo for Pain (MAPP) Study

NCT06720909
View directory record Official record
Conditions
Chronic Pain
Interventions
Mindfulness-Based Stress Reduction (MBSR), Open-Label Placebo (OLP), MBSR+OLP
Behavioral · Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 3, 2026, 2:11 AM EST
Completed Phase 3 Interventional Results available

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

NCT00035932
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir + ritonavir + tenofovir + nucleoside, Atazanavir + saquinavir + tenofovir + nucleoside, Lopinavir/ritonavir + tenofovir + nucleoside
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
29
States / cities
San Francisco, California • Torrance, California • Boulder, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2010 · Synced Nov 3, 2026, 2:11 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4355756 in Healthy Participants

NCT07765498
View directory record Official record
Conditions
Healthy
Interventions
LY4355756, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 3, 2026, 2:11 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants

NCT05818852
View directory record Official record
Conditions
Pain
Interventions
VX-548, Moxifloxacin, Moxifloxacin Placebo, VX-548 Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Nov 3, 2026, 2:11 AM EST
Terminated Phase 1 Interventional

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)

NCT01265199
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML)
Interventions
AT-406 in combination with daunorubicin and cytarabine
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years to 74 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Chicago, Illinois • Ann Arbor, Michigan • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Nov 3, 2026, 2:11 AM EST
Completed Phase 4 Interventional Results available

Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes

NCT01326533
View directory record Official record
Conditions
Pre-diabetes
Interventions
hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Nov 3, 2026, 2:11 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of VisionPure™ on Indices of Vision Health and Cognitive Function

NCT05533658
View directory record Official record
Conditions
Eye Health, Vision, Cognitive Function
Interventions
VisionPure Dietary Supplement, Placebo
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Lutz, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Nov 3, 2026, 2:11 AM EST
Completed Phase 1 Interventional

Pomegranate Extract Biomarker Study in Osteopenic Women

NCT01219140
View directory record Official record
Conditions
Osteopenic Women
Interventions
2 POMx Capsules, 2 placebo Capsules
Dietary Supplement
Lead sponsor
POM Wonderful LLC
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Nov 3, 2026, 2:11 AM EST
Recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

NCT06986174
View directory record Official record
Conditions
Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma, B-Cell Lymphoproliferative Disorder, Indolent Lymphoma
Interventions
Pacritinib
Drug
Lead sponsor
Shayna Sarosiek, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Nov 3, 2026, 2:11 AM EST
Terminated Phase 2 Interventional

Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

NCT01857817
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
VT-122, Placebo
Drug
Lead sponsor
Vicus Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Fayetteville, Arkansas • Santa Rosa, California • Parker, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Nov 3, 2026, 2:11 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Phenytoin for Memory Impairment Secondary to Megestrol

NCT02595723
View directory record Official record
Conditions
Cognitive Impairment
Interventions
Phenytoin 200 mg capsule, Megestrol 800 mg liquid, Phenytoin-matched Placebo capsule, Megestrol-matched liquid Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Nov 3, 2026, 2:11 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

NCT04002297
View directory record Official record
Conditions
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Interventions
zanubrutinib, bendamustine, rituximab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
60 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
12
States / cities
Orange, California • Chicago, Illinois • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 3, 2026, 2:11 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effects of SAMe in Patients With Alcoholic Liver Disease

NCT00573313
View directory record Official record
Conditions
Liver Disease, Alcoholic
Interventions
S-adenosylmethionine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
21 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 3, 2026, 2:11 AM EST
Completed Phase 2 Interventional Results available

2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis

NCT05274243
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
2-HOBA, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 3, 2026, 2:11 AM EST
Completed Phase 3 Interventional

A Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen and Naproxen Sodium in Postoperative Dental Pain

NCT05761574
View directory record Official record
Conditions
Pain
Interventions
Acetaminophen/Naproxen Sodium Fixed Combination, Naproxen Sodium, Acetaminophen, Placebo
Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
16 Years to 50 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Nov 3, 2026, 2:11 AM EST